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The unordered N-termini of parvovirus capsid proteins (Nt) are translocated through a channel at the
icosahedral ﬁve-fold axis to serve for virus trafﬁck. Heterologous peptides were genetically inserted at
the Nt of MVM to study their functional tolerance to manipulations. Insertion of a 5T4-single-chain
antibody at VP2-Nt (2Nt) yielded chimeric capsid subunits failing to enter the nucleus. The VEGFR2-
binding peptide (V1) inserted at both 2Nt and VP1-Nt efﬁciently assembled in virions, but V1 disrupted
VP1 and VP2 entry functions. The VP2 defect correlated with restricted externalization of V1-2Nt out of
the coat. The speciﬁc infectivity of MVM and wtVP-pseudotyped mosaic MVM-V1 virions, upon heating
and/or partial 2Nt cleavage, demonstrated that some 2Nt domains become intracellularly translocated
out of the virus shell and cleaved to initiate entry. The V1 insertion deﬁnes a VP2-driven endosomal
enlargement of the channel as an essential structural rearrangement performed by the MVM virion to
infect.
& 2012 Elsevier Inc. All rights reserved.Introduction
Viral capsids are nano-sized macromolecular containers
evolved to deliver nucleic acid at speciﬁc compartments of the
host cells. The trafﬁc of capsids from the surface receptor to the
appropriate compartment for disassembly to occur is driven by
protein signals, which are exposed to host factors following
programmed structural rearrangements in the capsid integrity
(Mercer et al., 2010). But natural virus features may be engi-
neered with heterologous peptides inserted at rationally selected
capsid protein domains. This strategy is being applied to retarget
viruses at speciﬁc cell types, use them as carrier of foreign
antigens, or to infer capsid functions in the life cycle.
The Parvoviridae, eukaryotic nuclear viruses containing a 5 kb
single stranded DNA genome in a 25 nm-diameter T¼1 icosahe-
dral nonenveloped capsid (Tijssen et al., 2011), are major candi-
dates for rational capsid retargeting as their 3-D atomic structure
is available from many members (e.g. Agbandje-McKenna et al.,ll rights reserved.
lmendral).
rk.
San Sebastia´n, Spain.
Langen, Germany.1998; Kontou et al., 2005; Kaufmann et al., 2004; Tsao et al.,
1991; Xie et al., 2002) and exhibit a wide host range and complex
biology. Common features of the parvoviral capsids are the
folding of the protein subunits into an eight-stranded antiparallel
b-barrel topology, a b-cylindrical projection encircled by a
canyon-like depression that surrounds the ﬁvefold symmetry
axes, and a pore at the center of the b-cylinder running between
the surface and the interior of the capsid. The capsid surface
however may drastically differ among the parvoviruses due to the
presence of prominent loops, depressions, or smooth surfaces
(Gurda et al., 2010), which confer characteristic functions.
Insertional mutagenesis of the Parvoviridae capsid with het-
erologous peptides yielded varying outcomes. Despite functional
constraints and deleterious effects of the heterologous peptides
on particles formation and infectivity, the Adeno-Associated Virus
(AAV) of the Dependovirus could be retargeted (Asokan et al.,
2010; Girod et al., 1999; Muller et al., 2003). The identiﬁcation of
permissive sites for large insertions (Warrington et al., 2004)
allows obtaining recombinant AAV viruses for multiple ongoing
gene therapy applications (reviewed in Vandenberghe et al.,
2009). Among the members of the autonomously replicating
Parvovirus genus, the insertion of the RGD motif on the Feline
Parvovirus (FPV) capsid surface severely impaired virus yield,
although allowed moderate transduction of certain human tumor
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the most exposed ordered surface loops of virus like particles
(VLPs) of the Canine (CPV), Porcine (PPV), and Minute Virus of
Mice (MVM) parvoviruses partly or completely impair stability
and assembly (Hurtado et al., 1996; Carreira et al., 2004). Never-
theless, the insertion of heterologous peptides at some positions
of loop 2 allowed chimeric VLPs of PPV and CPV to be produced in
amounts enough to induce speciﬁc antibodies against the inserted
epitope (Rueda et al., 1999). It should be noted however that VLPs
are not adequate particle entities to study virus retargeting, as
they assemble at non-physiological high amounts in the cyto-
plasm of insect cells (Yuan and Parrish, 2001; Riolobos et al.,
2010), disregarding the relevance of phosphorylation and signal-
mediated nuclear transport of intermediates in the natural
parvovirus assembly (Lombardo et al., 2000; Riolobos et al.,
2006, 2010).
Unordered capsid domains should better tolerate peptide
insertions. The n-termini (Nt) of the capsid proteins (VP) are
indeed ﬂexible sequences generally unresolved in the crystal struc-
ture of autonomous parvoviruses (Agbandje-McKenna et al., 1998;
Kontou et al., 2005; Tsao et al., 1991) and AAV (Xie et al., 2002),
with the exception of the n-terminus of the B19 Erythrovirus
major capsid protein, resolved adjacent to the b-cylinder
(Kaufmann et al., 2008). However these unordered Nt sequences
play important roles in the virus particle trafﬁc between cellular
compartments, as proposed for MVM (Maroto et al., 2004) and
subsequently for other parvoviruses (Sonntag et al., 2006;
Johnson et al., 2010), which must be taken into account when
infectious viruses are manipulated. The Nt of VP1 contains a large
unique region (VP1uR) that was shown to be essential for the
incoming parvovirus particle to initiate infection (Zadori et al.,
2001; Lombardo et al., 2002). Functional domains mapped at
VP1uR conferring infectious entry competence to the virus were:
(i) a conserved conventional nuclear localization sequence (NLS)
that targets the VP1 protein to the nucleus (Lombardo et al., 2002;
Sonntag et al., 2006; Vihinen-Ranta et al., 2002); (ii) a phospho-
lipase A2 (PLA2) motif that provides the virus with the means to
breach the endosomal membrane (Zadori et al., 2001; Girod et al.,
2002; Farr et al., 2005); and (iii) others as yet unclear functions
ascribed to clusters of basic amino acids (Lombardo et al., 2002)
and to PPXY motives (Cotmore and Tattersall, 2007).
The unordered n-terminal domain of the VP2 major capsid
protein (2Nt) is projected outside of the DNA-full parvovirus
particle through the ﬁvefold cylinder (Agbandje-McKenna et al.,
1998; Kontou et al., 2005; Tsao et al., 1991). These structural data
are consistent with the accessibility of 2Nt to proteases and
antibodies concomitantly with the maturation of DNA-ﬁlled
virions (Cotmore and Tattersall, 2007; Cotmore et al., 2010),
whereas this domain remains internal in puriﬁed empty native
capsids (Tattersall et al., 1977), or VLPs (Hernando et al., 2000).
Phosphorylation at three 2Nt serine residues by the Raf-1 kinase
was required for nuclear translocation of MVM assembly inter-
mediates (Riolobos et al., 2010) and nuclear egress of mature
virus in certain cellular hosts (Maroto et al., 2004), but it was not
relevant in the initiation of the infection (Maroto et al., 2000). The
2Nt domain may be cleaved from VP2 to form the VP3 protein
(Paradiso, 1981) by a chymotrypsin-like protease (Tattersall et al.,
1977; Paradiso et al., 1984; Tullis et al., 1992). This cleavage
occurs in the pH-dependent entry pathway of the members of the
Parvovirus genus (Weichert et al., 1998; Ros et al., 2002; Boisvert
et al., 2010; Parrish, 2010), soon after virus internalization (Mani
et al., 2006). In vitro, VP2/VP3 cleavage triggered a pH dependent
structural rearrangement of the MVM virion leading to VP1uR
externalization (Farr et al., 2006). However the function of
this cleavage in the infection is unclear as it could not be
prevented by either mutagenesis of the putative cleavage site(Tullis et al., 1992) or protease inhibitors (Cotmore and Tattersall,
2007), and viral stocks exhibiting variable VP2/VP3 ratios
(Tattersall et al., 1976, 1977) or even lacking VP3 subunits
(Maroto et al., 2004), were equally infectious.
We have investigated the suitability of the unordered Nt
domains for capsid display of heterologous peptides in an infec-
tious MVM particle. Since our long-term goal is to retarget the
genuine oncolytic parvovirus features (reviewed in Rommelaere
et al., 2010) to certain tumor cells, two different peptides with
afﬁnity for surface receptors of transformed cells were inserted:
(i) a single-chain antibody directed against the oncofaetal 5T4
antigen (Shaw et al., 2000), a tumor marker overexpressed in
malignant tumors (Fritsche and Mach, 1975); and (ii) the 7-mer
ATWLPPR peptide (Binetruy-Tournaire et al., 2000) ligand of the
vascular endothelial growth factor receptor type 2 (VEGFR2)
implicated in neoangiogenesis (Plate et al., 1992). These peptides
were tested for their compatibility with MVM assembly, viral
genome encapsidation, exposure on the capsid, and impact on the
infectivity of the engineered virions. This study sheds light into
the relevance of the conﬁguration of parvovirus assembly inter-
mediates for nuclear transport, and into the orchestrated intra-
cellular capsid structural rearrangement and cleavage that the
MVM virion must undergo for cell entry.Results
Defect of VP2/scAb-5T4 in nuclear translocation and capsid assembly
As a ﬁrst attempt on MVM retargeting by peptide insertion, the
large 286 amino acids long scAb-5T4 polypeptide (Lamikanra
et al., 2005) was engineered between residues Met1 and Ser2 of
the ﬂexible 2Nt domain in a VP2-only MVMi plasmid (see
Materials and methods). This strategy was adopted due to the
inability of full-size MVM vectors to encapsidate additional
foreign sequences larger than a few hundred nucleotides
(Kestler et al., 1999), and to the capacity of VP2 for forming
capsids by itself (Tullis et al., 1993), and being trans-complemen-
ted by VP1 for nuclear assembly (Lombardo et al., 2002). The
recombinant VP2/scAb-5T4 protein was expressed in transfected
NB324K cells at the expected size of about 140 kDa (Fig. 1A). To
study VP2/scAb-5T4 subcellular distribution and assembly in
respect to wtVP subunits, cells were transfected and stained by
IF with MVM-speciﬁc antibodies (a-VPs, a-VP1, and a-capsid),
and with an antibody recognizing the tag of sc5T4-myc. The VP2/
scAb-5T4 recombinant protein consistently accumulated as peri-
nuclear cytoplasmic aggregates failing capsid formation (Fig. 1B,
upper row), whereas wtVP proteins showed their characteristic
efﬁcient nuclear capsid assembly (Fig. 1B, lowest row).
In an attempt to rescue the nuclear uptake of some VP2/scAb-
5T4 subunits, we used the capacity of the MVMi capsid proteins
to cooperatively interact in the cytoplasm for nuclear import
(Lombardo et al., 2000, 2002). Indeed VP1, and more efﬁciently
VP2, wt capsid proteins allowed the co-transport of incompetent
VP mutant subunits (Lombardo et al., 2002), in keeping with the
VP composition of the two types of trimers that translocated into
the nucleus (Riolobos et al., 2006). To this end, VP2/scAb-5T4 was
co-expressed with both wtVP proteins, either singly expressed or
combined at the VP1:VP2 1:5 ratio found in the physiological
assembly intermediates (Riolobos et al., 2006), and their subcel-
lular distribution and capsid assembly phenotype assessed by IF
(Fig. 1B, middle three rows). Neither of the wt subunits, whether
expressed alone or in combination, was able to signiﬁcantly
facilitate the nuclear import of the VP2/scAb-5T4 protein, as the
sc5T4 signal remained cytoplasmic in all cases. On the contrary,
the expression of recombinant protein resulted in a signiﬁcant
Fig. 2. The V1 peptide inserted in the Nt sequence of both capsid proteins allows
efﬁcient MVMp nuclear assembly: (A) functional domains identiﬁed in the VP1-Nt
and VP2-Nt (named 2Nt) sequences of MVM capsid proteins (see Introduction),
and site of V1 insertion. VP1uR, VP1 unique region; NLS, nuclear localization
sequence; PLA2, phospholipase; BC, cluster of basic amino acids; NES, nuclear
export sequence. (B) Expression of wtVPs and recombinant VP-V1 proteins
accumulated by 106 NB324K cells at 48 hpt. (C) Assembly of VP-V1 subunits into
native capsids. Subcellular distribution of VP subunits (anti-VPs staining), and
capsid formation (B7-Mab staining), analyzed by confocal microscopy at 48 hpt in
NB324K cells transfected by the indicated molecular clones.
Fig. 1. Phenotypic effects of sc5T4 insertion in the MVMi major capsid protein: (A) expression of the recombinant VP2 protein harboring the sc5T4 insert. Extracts of
NB324K cells transfected with the indicated plasmids were subjected to blot-analysis with the anti-VPs antiserum. The ﬁgure shows the VP proteins accumulated by 106
cells at 48 hpt. (B) Subcellular distribution of the VP2/scAb-5T4 protein singly or co-expressed with wtVP proteins. NB324K cells were transfected with combinations of
MVMi plasmids, at the outlined ratios, expressing the VP2/scAb-5T4, VP1 (plasmid MVMiDVP2), or the VP2 (plasmid MVMiDVP1) protein. IF staining was perfomed with
the indicated speciﬁc antibodies. Central panels illustrate representative phenotypes as visualized by confocal microscopy, and the quantitative analysis examined by
epiﬂuorescence is shown to the right. Phenotypes were: mostly nuclear (N4C, black bars), mixed (N¼C, striped bars), and cytoplasmic (NoC, stippled bars). Percentages
are the average values scored at 48 hpt from at least 100 stained cells from two independent experiments.
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general capsid protein (Fig. 1B, bars to the right), suggesting that
the interaction with VP2/scAb-5T4 led to the cytoplasmic reten-
tion of wtVP subunits.
To explore whether some mosaic capsid containing VP2/scAb-
5T4 might be formed in the presence of wtVP proteins, homo-
genates of VP2/scAb-5T4 plus wtVP proteins co-transfected cells
were inoculated onto monolayers of NB324K, CT26neo, and 5T4-
antigen expressing CT265t4 cells (Mulryan et al., 2002), and
scored for VP and scAb-5T4 expression by IF. Only wtVP subunits
could be detected under these conditions, with less than one VP2/
scAb-5T4 transduced cell per 106 IFU, irrespective of the tested
cell line (data not shown). We concluded that the n-terminal
insertion of scAb-5T4 alters VP2 conﬁguration, making the
recombinant protein incompetent for nuclear import by itself,
as well as for cooperative interaction with other capsid subunits
that would allow its nuclear translocation. This effect eventually
precluded this strategy from being used to decorate MVM
particles with scAb-5T4.
Efﬁcient insertion of a short heterologous peptide in the MVMp native
capsid
To test whether a short peptide could be better tolerated in VP
intracellular transport and assembly, the VEGFR2-binding peptide
ATWLPPR (named V1; Binetruy-Tournaire et al., 2000) was
inserted at the same site but in the Nt sequence of both VP1
and VP2 capsid proteins of an MVMp infectious molecular clone
(Fig. 2A). The expression of the MVMp-V1 recombinant plasmid in
transfected NB324K cells showed that the peptide V1 insert
altered differently the electrophoretic mobility of the VP1-V1
and VP2-V1 proteins, which migrated faster and slower than the
equivalent wt VP subunits, respectively (Fig. 2B). The subcellular
distribution and assembly of the VP-V1 recombinant protein into
capsids was assessed with speciﬁc antibodies in transfected cells.
As shown in Fig. 2C, the bulk of the VP-V1 subunits translocated
into the nucleus (Fig. 2C, left) and assembled into capsids (Fig. 2C,
right) with efﬁciency comparable to the wt subunits, as apparent
from the intense nuclear staining with the Mab-B7 antibody that
recognizes a conformational epitope at the three-fold axis of the
MVM capsid (Kaufmann et al., 2007). Therefore, the V1 peptideinserted at the Nt domain preserved the VP proteins conﬁguration
required for the nuclear import and native capsid assembly
processes.
V1 insertion alters 2Nt exposure during virus maturation and cellular
uptake
To analyze MVMp-V1 virus maturation, transfected cells were
stained with an antibody raised against the 2Nt domain of MVMp
(Maroto et al., 2004), which is exposed outside of the coat in DNA-
ﬁlled virions but not in empty capsids (Tattersall et al., 1977;
Paradiso, 1981; Hernando et al., 2000; Cotmore and Tattersall,
2005). The analysis by confocal IF showed anti-2Nt intranuclear
staining in some MVMp-V1 transfected cells (Fig. 3A), although
the ratio of 2Nt/capsid expressing cells was estimated 11.972.8%
(nX200 transfected cells), which was several fold lower than the
41.477.1% ratio found in the transfection with the MVMp
infectious molecular clone. This result may indicate an impaired
Fig. 3. The MVMp-V1 virion fails to expose the V1-2Nt domain and to initiate
infection: (A) deﬁcient 2Nt exposure by VP-V1 subunits assembled in capsids.
Confocal IF microscopy of NB324K cells transfected by the MVMp and MVMp-V1
plasmids analyzed for capsid formation (capsid), and 2Nt exposure (a2Nt) at
48 hpt. (B) MVMp-V1 forms DNA-ﬁlled virions. Viral particles produced in cells
transfected with the indicated plasmids were resolved in sucrose gradients. Total
capsids (determined as hemagglutination units, HAU) and virions (determined by
slot-dot DNA hybridization) were quantitated across the gradients. Examples of
fractions corresponding to empty capsids (C) and DNA-ﬁlled virions (V) from
3106 transfected cells are shown. (C) Resistance of the 2Nt-V1 domain to
cleavage long-term post-infection. 35S-labeled puriﬁed MVMp (5103 cpm) and
MVMp-V1 (103 cpm) full virions (V, right), and their respective empty capsids
(C, left; 3104 cpm each), were inoculated onto monolayers of 105 NB324K cells
and harvested at the indicated hpi. The fate of capsid proteins was analyzed by 8%
SDS-PAGE and 4 days exposure to a phosphoimager system (Fuji). (D) Failure of
MVMp-V1 to propagate in transfected cultures. Shown are the percentages of
NB324K cells expressing VP proteins (IF staining) estimated from randomly
chosen ﬁelds (n¼200). The experiment was performed twice with similar out-
come. (E) Speciﬁc infectivity of puriﬁed MVMp and MVMp-V1 virions. NB324K
monolayers were inoculated with normalized amounts of these virions and
infectious titers determined by IFA at 24 hpi. Data are the average with standard
error bars from three independent determinations.
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in the MVMp-V1 genome encapsidation.
The pore at the 5-fold axis of parvovirus capsid, through 2Nt
becomes externalized, has been suggested to serve as the entry
portal for viral DNA (Bleker et al., 2005; Cotmore and Tattersall,
2005; Plevka et al., 2011). Therefore, the V1 insertion at thisdomain could hamper genome encapsidation in preformed cap-
sids. To quantitatively study the efﬁciency of MVMp-V1 genome
encapsidation, viral particles isolated from transfected cells were
resolved by centrifugation through sucrose gradient, and the ratio
between empty capsids and DNA-ﬁlled virions formed compared
to MVMp. As exempliﬁed in Fig. 3B, the amount of virions formed,
in respect to total capsid yield, was similar for MVMp and MVMp-
V1 transfected samples. MVMp-V1 virions behaved in the gradi-
ents as MVMp even under mild detergent, suggesting proper
genome packaging. This result indicated that the V1 peptide
allows efﬁcient MVM capsid formation and viral genome encap-
sidation, but the maturing MVMp-V1 virions fail to efﬁciently
externalize the 2Nt domain out of the cost.
We next investigated the behavior of the V1-2Nt domain
during early events of the virus life cycle, namely cell interaction
and entry. Virus binding to cells was not signiﬁcantly perturbed
by the V1 peptide insertion, since the fraction of empty capsids
and input virions that became NB324K cell-associated under non-
saturating conditions was similar for MVMp-V1 and MVMp
(Fig. 3C). Next, the integrity of the VP subunits was investigated
with puriﬁed 35S-labeled MVMp and MVMp-V1 viral particles
analyzed for several days post-infection. Unlike the variable
proportion of VP2 to VP3 cleavage commonly found in viral
stocks of MVM and other parvoviruses harvested from cultures
showing cytopathic effects (Tattersall et al., 1976; Paradiso, 1981;
Santaren et al., 1993; Maroto et al., 2004; Mani et al., 2006),
preparations of MVMp-V1 virions puriﬁed from transfected cul-
tures consistently lacked VP3 (Fig. 3C). Moreover, while the VP
proteins in both types of empty particles remained unchanged
over lasting post-infection periods, a VP2 to VP3 cleavage in
MVMp virions was noted within the ﬁrst 4 h post-binding, but at
no time following inoculations with the MVMp-V1 virion. These
data conﬁrmed the lasting restricted exposure of 2Nt out of the
capsid shell in cell-associated MVMp-V1 virions.
The V1 peptide impairs an early stage of MVMp life cycle
The efﬁcient assembly of VP-V1 into virus particles led us to
investigate any putative effect of the inserted peptide on MVM
infectivity. The capacity of newly produced MVMp-V1 virions to
propagate in culture was studied by IF of transfected NB3234K
cells. In wtMVMp genuine transfections, an efﬁcient viral propa-
gation was denoted by a drastic increase in the percentage of VP
expressing cells (VPþ) from 48 to 96 hpt, so that most cells in the
culture became eventually infected (Fig. 3D). In MVMp-V1 DNA
transfections, the percentage of cells expressing capsid proteins at
48 hpt was comparable to the wt case, but this proportion did not
increase at post-transfection times. Instead, VP-V1 expressing
cells signiﬁcantly declined by 96 hpt (Fig. 3D), and the remaining
VPþ cells showed cytopathic signs presumably mediated by viral
products. At late postransfection times, VPþ cells became vir-
tually absent from MVMp-V1 transfected cultures, which got
overgrown with non-transfected cells (not shown). This experi-
ment indicated that the V1 peptide hampered MVMp infectivity,
preventing transfection-derived MVMp-V1 virions from spread-
ing to and infecting neighboring cells.
The V1 insert might interfere with the 2Nt nuclear export
activity (Maroto et al., 2004), i.e. with the release of MVMp-V1
virions from transfected cells, and/or with the capacity of the
formed virions for initiating secondary rounds of infection. The
latter possibility was suggested by the above mention failure of
the MVMp-V1 virions to propagate in transfected cultures under-
going lysis. In order to verify a possible deﬁciency of MVMp-V1 to
initiate infection, DNA-full MVMp-V1 and MVMp virions har-
vested early at 48 hpt to avoid possible differences due to
reinfections (Lang et al., 2005), were gradient-puriﬁed from
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infectivity measured in a single infection cycle. Inoculations with
normalized amounts of viral particles showed that the speciﬁc
infectivity of the MVMp-V1 virion was close to 104 fold lower
than that of the MVMp (Fig. 3E). A similar result was obtained in
A9 mouse ﬁbroblasts (not shown; see related data below in
Fig. 5B), indicating that the V1-dependent restriction of MVMp
infection operates in different permissive cell types. It was thus
concluded that the MVMp-V1 virion is functionally deﬁcient in an
early step of the infection cycle.
Partial in vitro removal of V1 does not confer infectivity to MVMp-V1
The failure of the V1-2Nt domain to be exposed on nuclear
maturing virions and cleaved in inoculated cells (Fig. 3A and C),
may relate to a deﬁcient structure of the MVMp-V1 virion itself.
To study this hypothesis, puriﬁed MVMp and MVMp-V1 virions
were subjected to digestion with speciﬁc proteases in vitro at neutral
pH, and the integrity of their VP proteins assessed by SDS-PAGE.
Fig. 4A depicts the entire sequence of the V1 peptide inserted at the
2Nt of MVMp, as well as the consensus cleavage site for some
proteases used here and in other studies. As it was previously
described (Tattersall et al., 1977; Paradiso et al., 1984; HernandoFig. 4. Susceptibility of the MVMp and MVMp-V1 virions to in vitro treatment
with proteases: (A) potential protease cleavage sites in the entire V1-2Nt sequence.
The three phosphoserine residues (Maroto et al., 2000), and consensus cleavage sites
for trypsin (T), chymotrypsin (Ch) and V8 protease (V8), are highlighted.
(B) Sensitivity of puriﬁed virions to proteases-driven VP protein cleavage. Equivalent
amounts (0. 01 mg) of puriﬁed MVMp and MVMp-V1 virions were subjected to
digestion with trypsin (0.02 mg, T1; 0.5 mg, T2), chymotrypsin (1 mg, Ch), or V8 protease
(1 mg, V8) for 30 min at 37 1C, and then VP proteins integrity was analyzed by western-
blotting after 8% SDS-PAGE. A representative experiment is illustrated. V: untreated
puriﬁed virions. (C) Effect of in vitro protease digestions on MVMp and MVMp-V1
infectivity. Puriﬁed virions digested with proteases (T at the higher dose), whose VP
proteins pattern is shown in (B), were inoculated onto NB324K monolayers, and the
number of infectious units determined by IFA. Bars are average values from ﬁve
experiments with standard deviation errors.et al., 2000; Maroto et al., 2004; Farr et al., 2006), trypsin quantita-
tively cleaved VP2 subunits of MVMp to VP3, even at the lower
assayed dose (Fig. 4B, upper left panel). However, the VP2-V1
subunits of the MVMp-V1 virion was cleaved to VP3 by trypsin in a
much lower proportion, as half of the VP2-V1 subunits remained
uncleaved at the higher trypsin dose (Fig. 4B, lower left panel).
Control digestions with heat-disassembled native empty capsids
(Hernando et al., 2000; Riolobos et al., 2010) showed similar
susceptibility to trypsin of the wt and recombinant VP proteins (data
not shown). Regardless of a possible cleavage of the V1 peptide at its
Arg7 residue, the shift in size between VP2-V1 and VP3 (Fig. 4B)
suggested that, as determined by direct amino acid sequencing for
MVMp (Tullis et al., 1992) and the closely related H-1 parvovirus
(Paradiso et al., 1984), the Arg22 residue become accessible to trypsin
in the externalized V1-VP2 subunits of the MVMp-V1 virion. Simi-
larly, only about one-third of the VP2-V1 protein could be cleaved by
chymotrypsin to a VP3 like protein, at the dose that cleaved most,
although not all, wt VP2 subunits (Fig. 4B, right panels). The VP2 of
both viruses was resistant to the V8 protease, suggesting that the
three phosphoserine residues that modulated its sensitivity to pro-
teases (Maroto et al., 2000), are conserved in the V1-2Nt domain as
well. The limited number of V1-VP2 subunits that can be cleaved by
proteases in vitro agreed with the above mention ﬁndings in cells,
conﬁrming that the V1 insertion severely impairs the exposure of the
2Nt domain outside of the virion shell.
If VP2 cleavage is important for MVM infection, the deﬁcient
speciﬁc infectivity of the MVMp-V1 virions (Fig. 3D and E) may lie
in the impaired V1-2Nt exposure (Fig. 4B), which would preclude
its proteolytic cleavage observed in inoculated cells (Fig. 3C). To
explore this hypothesis, samples of both puriﬁed virions were
subjected to proteases digestions as above, partially removing the
V1-2Nt domain in some cases, and quantitatively compared with
untreated virions for the ability to infect NB324K cells. As shown
in Fig. 4C, these predigestions had no negative effects on the
highly speciﬁc infectivity of MVMp, but failed to signiﬁcantly
improve the capacity of the MVMp-V1 virions to initiate infection.
Since protease-treated MVMp-V1 and MVMp virions should have
similar surface properties, these results suggest that virus struc-
tural constraints operating inside the cells must contribute to the
early blockade of MVMp-V1 infection.
V1 insertion disrupts VP1 and VP2 functions required for MVM cell
entry
To investigate the nature of the intracellular blockade that
enables the V1-MVMp virion to initiate infection, we ﬁrstly
considered the possibility that the V1 coding sequence was
interfering through a mechanism operating in cis at the DNA
level, with the transfer of the parvoviral genome across the
nuclear envelope and its conversion into a transcription template.
For this purpose, the MVMp-V1 genome was coated with com-
plementary wt capsid subunits provided in trans, and the formed
mosaic viruses tested for their competence to initiate infection.
Fig. 5A shows examples of recombinant and wt VP expression in
these co-transfection assays. A marked rescue of infectivity close
to 103-fold was achieved by packaging MVMp-V1 DNA with wt
capsid proteins provided through trans-complementation by
either a replication-defective full-length pUC19MVMp clone, or
by a plasmid only expressing the wtVPs (Fig. 5B). Positive
complementation was consistently obtained in NB324K as well
as A9 cells (Fig. 5B, below), indicating that it was not cell-type
dependent. This result indicated that the MVMp-V1 genome can
be efﬁciently delivered to the nucleus of MVMp permissive cells,
and thus the deﬁciency of MVMp-V1 virion in infection must be
due to a dysfunction of the V1-carrying capsid during the entry
process.
Fig. 5. Rescue of MVMp-V1 virion infectivity by trans-complementation with
wtVP proteins. Homogenates of NB324K cells co-transfected with the indicated
plasmids combinations were normalized for the amount of expressed VP proteins,
and the number of infectious virus determined by IFA: (A) Western-blotting
showing examples of VP expression in transfected cells. (B) IFU titers determined
in NB324K (upper) and A9 (lower) cells. Titers are the mean with standard errors of
samples inoculated in triplicate from at least two transfection assays. Plasmid
acronyms are: Mp, genomic MVMp; MpV1, genomic MVMp-V1; VPs, pSVtk-VP2/VP1;
pMp, non-infectious pUC19MVMp; pMpDVP1 and pMpDVP2, are pUC19MVMp
derivatives respectively lacking either the VP1 or the VP2 protein. IFU values from
single transfections with the plasmids VPs, pMp, pMpDVP1 and pMpDVP2, were
consistently below the DL and are not represented.
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by V1 during the entry process, we quantitatively determined the
competence to initiate infection of MVMp-V1 virions complemented
in trans by either VP1 or VP2 wt protein subunits. MVMp-V1 was co-
transfected with non-replicative pUC19MVMp derivative clones
expressing only the VP1 or the VP2 proteins obtained by cDNA
cloning (see Materials and methods), and their infectivity tested by
IFA. In contrast to the MVMp-V1þpUC19MVM co-transfection,
pseudotyping with singly expressed VP1 or VP2 wt subunits did
not confer signiﬁcant infectivity to the MVMp-V1 chimeric virion
(Fig. 5B). These results demonstrated that the V1 insertion suppresses
both VP1 and VP2 functions required for MVM cell entry.
Intracellular de novo 2Nt exposure is essential for MVM to onset
infection
We next addressed the nature of the VP2 functional defect
imposed by the V1 insertion and its relationship to the VP2/3
cleavage. To this aim, mosaic MVMp-V1 virions pseudotyped withsupplementary wt subunits, either with both VPs (MVMp-V1/VPs
virion), or only with VP1 (MVMp-V1/VP1 virion), were produced
and puriﬁed (see Materials and methods), and their speciﬁc
infectivity related to VP2 cleavage. These mosaic virions were
composed of wt and recombinant proteins at similar equimole-
cular ratios (Fig. 6A, upper), probing the efﬁcient assembly of the
V1-VP subunits in the MVM capsid. Yet, the MVMp-V1/VPs virion
showed a high speciﬁc infectivity (Fig. 6A, lower) close to that of
MVMp (Fig. 3E), in sharp contrast to the very low speciﬁc
infectivity of the MVMp-V1/VP1 virion similar to that of MVMp-
V1 (Fig. 3E). Since both mosaic virions harbor the MVMp-V1
genome, and their coat contains a similar ratio of VP1/VP1-V1
subunits, this result supported in puriﬁed virions the observations
outlined in Fig. 5, on the capacity of V1 to disrupt VP2 functions
needed for MVM cell entry. Importantly, substantial cleavage of
VP2 and VP2-V1 subunits could be obtained in both types of
virions at high dose of trypsin and neutral pH (Fig. 6A, upper), but
the digested virions maintained their characteristic distinct spe-
ciﬁc infectivities (Fig. 6A, lower). The inability of the trypsin-
digested MVMp-V1/VP1 virion to infect, even though it carries a
signiﬁcant proportion of VP3 (resulting from the VP2-V1 clea-
vage-off) and wtVP1 subunits, provided direct evidence that VP3
cannot execute VP2 entry functions.
The requirement of VP2 for MVM entry, although extracellular
VP2/3 cleavage did not activate MVMp-V1 virion infectivity (Figs. 4C
and 6A), focused our study on a putative function of intracellular
VP2/3 cleavage in the infection. Puriﬁed wtMVM virus subjected to
different trypsin doses, which did not impair infectivity (Fig. 4), was
analyzed for VP2/3 ratio prior and after infection. A low but
signiﬁcant proportion of VP2 subunits remained uncleaved in vitro
even at doses of trypsin ten times in excess of that cleaving most
subunits (Fig. 6B). However, an additional cleavage of a high propor-
tion of the remaining VP2 was consistently observed in the virus
samples harvested 4 hpi (Fig. 6B, lower panel). This experiment
showed that, regardless the VP2/VP3 ratio of the incoming particle,
some 2Nt domains undergoes inside the cells a de novo exposure and
cleavage-off the capsid as the virus initiates infection. To further
investigate this evidence, wtMVM was subjected to increasing
temperature andmonitored for VP2 exposure and cleavage in relation
to infection. The virus infectivity was sensitive to heat at tempera-
tures 55 1C or higher (Fig. 6D) without alteration of the VP composi-
tion (Fig. 6C, upper panel). VP2 subunits of viruses heated at
temperatures that essentially unaltered infectivity (below 55 1C) were
sensitive to trypsin in vitro and further extensively cleaved in cells
(Fig. 6C and E), in agreement with data shown in Fig. 6B. However,
VP2 subunits of viruses signiﬁcantly inactivated by heat (above 55 1C)
were less sensitive to trypsin and moreover fail to undergo a
signiﬁcant additional cleavage in the cells (Fig. 6C and E). While the
heat-induced capsid rearrangement lowering VP2 accessibility to
proteases might result from competing VP1 subunits externalized at
these temperatures (Cotmore et al., 1999, 2010), the extent of
infectivity inactivated by heat approximately correlated with the
defect of VP2/VP3 cleavage ratio in cells. In summary, these diverse
analyses suggested that the MVM infection implies an intracellular
exposure and cleavage of some VP2 subunits, which becomes
impaired as the virus is heat-inactivated, and cannot be accomplished
by the non-infectious MVMp-V1 virion.Discussion
MVM coat manipulations are restricted by the dependence on the
conﬁguration of assembly intermediates for nuclear import
A scAb speciﬁc for the 5T4 tumor antigen (scab-5T4) was
inserted at the 2Nt domain of the MVM coat addressing the
Fig. 6. VP2 cleavage in the initiation of MVM infection: (A) puriﬁed mosaic MVMp-V1 virions pseudotyped with both VPs (MVMp-V1/VPs), or with VP1 only (MVMp-V1/
VP1) wt capsid subunits tested for VP2 cleavage and infectivity. Upper: Western-blot analysis of puriﬁed mosaic virions (I), and upon trypsin digestion (T). Samples (5 ng
each) were subjected to long-run 8% SDS-PAGE to resolve the protein species indicated at the margin. Lower: speciﬁc infectivity of the same samples. Results are the mean
with standard errors obtained from two preparations inoculated in triplicate. (B) Blot analysis (15 ng per sample) of input MVMp (I), of virus digested with the indicated mg
of trypsin (T), and of trypsin-digested virus then subjected to 4 hpi in NB324K cells at 37 1C (TC). Lower panel, VP2/3 ratio in the blot measured by densitometry. (C) Input
MVMp (I) heated to the indicated temperatures (1C; rt, room temperature), was then subjected to trypsin digestion (0.1 mg) and, either bound 1 h to NB324K cells at 4 1C
(T), or used to infect NB324K cells for 4 h at 37 1C (TC). (D) Quantiﬁcation by plaque assay of the infectious virus remaining upon heating. (E) VP2/3 ratio resulting from the
three respective treatments (I, T, and TC blots, in panel (C)), as determined by densitometry. Representative results from at least three independent experiments performed
with two MVMp preparations are shown. a.u., arbitrary units of densitometry (BioRad GS-800).
C. Sa´nchez-Martı´nez et al. / Virology 432 (2012) 45–56 51feasibility to endow this autonomous parvovirus with speciﬁc
oncotropism. Genetic insertions of scAb were feasible in the
envelope of RNA viruses maturing in the cytoplasm or at the
plasma membrane (Hammond et al., 2001; Marin et al., 1996),
and in the capsid of some nuclear-replicating non-enveloped DNA
viruses as adenoviruses (van Beusechem et al., 2002; Kashentseva
et al., 2002) and AAV (Yang et al., 1998). We failed though to
incorporate the scAb-5T4 in the MVMi capsid, in spite of the fact
that the insertion lays in the 2Nt ﬂexible domain. The VP2-sc5T4
protein was blocked at the perinuclear region, suggesting a defect
in the conﬁguration of a putative VP2/scAb-5T4 assembly inter-
mediate. The nuclear import of VP2-sc5T4 could not be comple-
mented by coexpression of wtVP proteins (Fig. 1B). Instead, the
VP2-sc5T4 protein signiﬁcantly retained wt subunits in the
cytoplasm, precluding their otherwise efﬁcient nuclear transport
as oligomers (Riolobos et al., 2006, 2010). The VP2-sc5T4/wtVP
hetero-oligomers may acquire a cytoplasmic conﬁguration not
competent for nuclear import.
In contrast to these results, a recombinant protein combining
the parvovirus AAV capsid protein and a CD34-speciﬁc sFv
fragment could be included in chimeric vectors (Yang et al.,
1998), as signiﬁcant titers of speciﬁc CD34þ transducing particles
were achieved (Yang et al., 1998). Likewise, large peptide inserts
(up to 30 kDa) were successfully incorporated in the N-terminus
of the VP2 capsid protein of vectors based on AAV (Warrington
et al., 2004). The present study though points out that the
autonomous parvovirus capsid may not tolerate large heterolo-
gous peptides, even in the unordered 2Nt domain, due to
incompetence for cytoplasmic proper assembly and/or nuclear
transport competence of the recombinant proteins. Although this
rule was obtained from a single insertion, it is supported by a
similar cytoplasmic phenotypes previously reported for MVMi
capsid proteins harboring short distal deletions, which was traced
back to a VP2 folding alteration hampering the function of the
structured nuclear localization motif (NLM; Lombardo et al., 2000).
Therefore a fundamental difference in the assembly process betweenvirus members of the Parvoviridae may be suggested. The transport
function of the NLM, which beta-stranded conﬁguration is conserved
within the Parvovirus genus, may be more sensitive to genetic
insertions altering the overall VP conﬁguration than the equivalent
AAV nuclear transport sequence to be identiﬁed.
Insertion of a short peptide at Nt sequences allows efﬁcient assembly
of recombinant MVM virions
The insertions of small heterologous peptides in most surface
loops of VLPs of CPV, PPV, and MVM severely impaired particles
yield (Carreira et al., 2004; Hurtado et al., 1996), although
insertions at loop 2 allowed signiﬁcant recoveries of recombinant
VLPs (Rueda et al., 1999). These reports pointed to structural
constraints imposed by the ordered domains of the capsid of the
Parvovirus genus to the insertion of heterologous peptides. The
ﬂexible 2Nt domain allowed however better tolerance to peptides
insertion in VLPs of CPV and PPV (Sedlik et al., 1997), in
agreement with the hereby reported proﬁciency of MVM native
capsid in packaging the V1 peptide inserted at the Nt sequence of
VP1 and VP2 (Fig. 2).
Much less attention has received the biological effects of
heterologous peptides in autonomous parvovirus particles pro-
duced in the natural cell host. A peptide inserted at ordered
domains of the FPV capsid resulted in low production of the
recombinant virus (Maxwell et al., 2001). In contrast, we show in
this work an efﬁcient yield of mature DNA-ﬁlled MVMp-V1
virions (Fig. 3B). V1 insertion allowed unrestricted viral genome
encapsidation, a phenomenon that follows the formation of an
MVM empty capsid (Maroto et al., 2004), and that is believed to
occur through a portal at the ﬁvefold pore (Bleker et al., 2005;
Cotmore and Tattersall, 2005; Plevka et al., 2011). Insertion at the
Nt sequences may thus become a promising strategy to produce
parvovirus virions bearing biologically active peptides, although
infectivity can be severely compromised by the interplay between
a particular peptide conﬁguration and VP functions (see below).
Fig. 7. Model of the 2Nt function in MVM cell entry. Extracellular (upper): viruses
undergoing dynamic exposure and cleavage of variable numbers of 2Nt domains
can equally bind to the sialicilated receptor (SR) and get internalized. Intracellular
(lower): (A) at the low endosomal pH most remaining 2Nt are de novo extruded
out of the virion coat enlarging the functional diameter of the 5-fold channel.
(B) As the exposed 2Nt are cleaved-off, a subsequent externalization of the entire
VP1-Nt through one or a few enlarged channels sufﬁces the virus to escape from
the endosome. Both (A) and (B) dynamics of Nt sequences at the channel are
blocked by the V1 peptide insertion.
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MVM capsid
The 2Nt domain is extruded outside the virus coat during
genome encapsidation (Cotmore and Tattersall, 2005) through the
channel at the 5-fold axes of MVM capsid. The crystal structure of
CPV, MVM, and other parvovirus capsids, shows one single
polypeptide chain running through the narrow channel (Tsao
et al., 1991; Agbandje-McKenna et al., 1998; Kontou et al., 2005),
so that a maximum of 11 subunits can be exposed at a time on the
coat of mature virus, provided one may be occupied by the virus
genome (Cotmore et al., 2010). However the large proportion of
VP2 subunits that can be cleaved by trypsin in vitro (e.g. Paradiso
et al., 1984; Tattersall et al., 1977; Maroto et al., 2004) supports a
dynamic model in which the residual 2Nt are subsequently
externalized as the protease releases the pore occupancy (Farr
et al., 2006; Cotmore and Tattersall, 2007). The V1 insert clearly
disables the MVMp-V1 virion from undergoing this structural
dynamics at the pore, since close to half of the VP2-V1 subunits
remained intact after protease digestion at neutral pH in vitro,
under conditions allowing most wt VP2 subunits to be cleaved
(Fig. 4B). Hence, steric hindrances to capsid dynamics can be
assured to lie in the V1 peptide, whose bulky (W) and destructur-
ing (P) residues, not present in the 2Nt sequence, would counter-
act the extrusion force from the interior of the virus particle. In
vivo, the deﬁcient IF staining of the V1-2Nt domain in transfected
cells (Fig. 3A), indicated that the half-life exposure of this domain
on the maturing MVMp-V1 virion coat is also severely reduced.
Moreover a complete lack of cleavage of the V1-2Nt domain was
observed in inoculated cells (Fig. 3C), suggesting that these
hindrances get stronger as the entering virions trafﬁc across the
endosomal compartment, which may be related to the low pH-
dependent constriction of the pore by leucine side chains
(Farr and Tattersall, 2004).
The V1 peptide insertion severely impaired also VP1-Nt func-
tions required for MVM cell entry (Fig. 5B). Several functions
essential for the virus to breach the endosomal membrane and
trafﬁc to the nucleus were mapped in the VP1uR sequence
(Introduction and Fig. 2A), and VP1-Nt became externalized out
of the coat at low pH in vitro (Farr et al., 2006), and during CPV
and MVM infections (Vihinen-Ranta et al., 2002; Mani et al.,
2006), although the length of the externalized sequence has not
being determined yet. It seems unlikely that the V1 peptide
inserted at the 143 residue of VP1uR c-terminus disrupt the
upstream VP1 functional domains, as the bulky (W) and structure
distorting (P) residues of V1 are extensively represented in the
VP1uR sequence (Astell et al., 1986; Lombardo et al., 2002; Farr
et al., 2005). Rather, paralleling the effect caused on 2Nt
(Figs. 3 and 4), V1 may restrict the externalization out of the coat
of the VP1-Nt c-terminus as well, which sequence is shared with
2Nt. This hypothesis (currently under study) would suggest that
an externalization of the entire disordered VP1-Nt sequence is
required for the infection (see model in Fig. 7, below), high-
lighting the metastability of the MVM virus particle.
Endosomal VP2-driven enlargement of the capsid channel initiates
MVM infection
The importance of VP2 to VP3 cleavage in the infection of
MVM and other autonomous parvoviruses has been a controver-
sial issue, since wt viruses are equally infectious regardless the
relative VP3 contain (e.g. Tattersall et al., 1976), and newly
matured MVMp virions lack VP3 subunits even though they are
fully infectious (Maroto et al., 2004). In consistency with this, the
VP2 proteolytic cleavage in vitro lacked any effect on the
infectivity of the MVMp virions (Fig. 4). In cells, the VP2 cleavageoccurs following binding (Fig. 3C) at the low pH of early endo-
somes (Mani et al., 2006), but the difﬁculty to block it by
introducing mutations in the putative cleavage site (Tullis et al.,
1992), or by treating infected cells with proteases inhibitors
(reviewed in Cotmore and Tattersall, 2007), has complicated an
understanding of its role in the infection. The V1 peptide insertion
caused an unprecedented genetic inhibition of both VP2 cleavage
in cells (Fig. 3C) and MVMp infectivity (Fig. 3D and E), which was
what prompted us to investigate this process further.
This study shows a key role exerted by the 2Nt domain in
shaping an entry competent conﬁguration of the MVM coat, as
VP3 cannot accomplish the essential entry functions harbored by
VP2. This conclusion stands from the inability to infect of two
types of viral particles bearing a large proportion of VP3 subunits,
namely the trypsin-digested chimeric (Fig. 4B and C), and the VP-
pseudotyped (Fig. 6A), MVMp-V1 virions. Further analyses with
wt virus subjected to trypsin and/or heat (Fig. 6B–E) correlated
the VP2 entry function with an intracellular cleavage of some
subunits, which became therefore exposed out of the capsid as
the virus route through the low endosomal pH. These experi-
mental observations collectively support a model for the function
of the 2Nt domain of VP2 in MVM entry (outlined in Fig. 7).
Charge repulsion and steric pressure of the encapsidated viral
genome enhanced at low pH would determine an intracellular de
novo exposure of 2Nt domains outside the capsid. This process
would force the narrow ﬁvefold channel to adopt an enlarged
conﬁguration, which would structurally tolerate the subsequent
externalization of the entire VP1-Nt (discussed above). The con-
nection between both Nt processes is supported by previous
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for VP1uR externalization in vitro (Farr et al., 2006), and that
VP1uR becomes accessible to antibodies during MVM cell entry
concomitantly with 2Nt cleavage-off (Mani et al., 2006). A limited
number of VP2-driven open channels may fulﬁll virus infectious
trafﬁc to the nucleus by one or a few exposed VP1-Nt domains.
The removal of 2Nt domains harboring a nuclear export signal
(Maroto et al., 2004) would ultimately facilitate the stable nuclear
accumulation of the incoming virus.
Capsid cleavage in nonenveloped virus entry
Proteolytic cleavage of the viral particle is a common mechan-
ism used by different types of nonenveloped viruses to penetrate
or disrupt cellular membranes during entry (Tsai, 2007). In some
systems the virus may be activated in vitro by a protease cleavage
prior to cell inoculation (Richards et al., 2006), whereas in others
a lytic peptide with endosomal membrane-interacting activity
must be intracellularly released from the virion for full activity
(Odegard et al., 2009; Chandran et al., 2002). In the nonenveloped
autonomous parvoviruses the cleavage of a small capsid peptide
results from profound capsid structural rearrangements devel-
oped in the endosome, which trigger the exposure of disordered
Nt domains required to open the capsid channel (2Nt) and
penetrate the endosomal membrane (VP1uR).
Other members of the Parvoviridae may not undergo capsid
cleavage for entry, reﬂecting distinct Nt exposure mechanisms.
For example, the Nt sequences of AAV became externalized
during virus trafﬁc without detectable cleavage (Sonntag et al.,
2006), whereas in B19 the 2Nt conﬁguration was resolved on the
capsid (Kaufmann et al., 2008) and the VP1uR became accessible
to the virus surface upon receptor attachment without capsid
cleavage (Bonsch et al., 2010; Ros et al., 2006). The requirement of
an intracellular capsid cleavage for MVM infection may open up
new prospects for re-targeting some members of the Parvoviridae
to cancer cells. The VP2 cleavage site could be manipulated so as
to make it exclusively susceptible to proteases overexpressed in
tumor cells, in which the initiation of parvovirus infection would
be speciﬁcally facilitated. This study shows that such approaches
must select for upregulated proteases that access the endosome
and function at low pH, and should not perturb the required VP2-
driven enlarging of the ﬁvefold channel.Conclusions
This work illustrates the usefulness of a peptide insertion
approach to gain insights into the functional roles that unordered
Nt domains of capsid proteins play in virus assembly and cell
entry. The insertion of peptides at the N-terminal domains of
parvovirus MVM structural proteins has shown that folding of
assembly intermediates, opening of narrow capsid channels, and
externalization out of the coat of long disordered sequences, are
essential processes for the life cycle of this T1 metastable virus.
These ﬁndings provide new clues to understand capsid functions
of noneveloped viruses, and warn against the functional tolerance
of their disordered domains for retargeting purposes.Materials and methods
Cell lines
The A9 ouabr11 mouse ﬁbroblast cell line and the NB324K
simian virus 40-transformed human newborn kidney cell line,
were maintained under minimal number of passages in DulbeccoModiﬁed Eagle Medium (DMEM) supplemented with 5% heat-
inactivated fetal calf serum (FCS; Gibco BRL). These cell lines are
routinely used for parvovirus MVM production (Gardiner and
Tattersall, 1988). The CT26-neo and CT26-5T4 cell lines (Mulryan
et al., 2002) were cultured in RPMI-10% FCS medium and, when
required, selected for resistance to neomycin (G418, Gibco,
400 mg/ml).
Plasmids and cDNA constructs
The collection of plasmids used included the original infectious
molecular clones of the prototype (pMM984; Merchlinsky et al.,
1983) and the immunosuppressive (pMVMi; Gardiner and
Tattersall, 1988) MVM strains. MVMp derivative plasmids were
a non-infectious full genome pUC19MVMp lacking the hairpins,
and the pSVtk-VP2/VP1 plasmid expressing capsid proteins
(Ramirez et al., 1995). To obtain VP2 and VP1-only expressing
replicative-defective MVMp clones (named pUC19MVMpDVP1
and pUC19MVMpDVP2 respectively), cDNA clones were con-
structed based on the splicing patterns of the minor intron
(Jongeneel et al., 1986; Morgan and Ward, 1986). For this
purpose, total mRNA isolated from MVMp infected NB324K cells
(MOI 10) at 20 hpi was retrotranscribed priming with oligodT
(Promega, ImProm-IITM) and ampliﬁed by PCR (PfxPlatinums
polymerase, Invitrogen) with the junction-speciﬁc oligonucleo-
tides (50–30; Isogen Bioscience or Sigma) GAC ACC GAA AAG TAC
GCC TCT CAG (nt 2012–2035 of MVMp genome; Astell et al.,
1986) and GAA AAA GCA TGG TTA GTT AGT AAG (nt 4573–4550).
The PCR ampliﬁcation product was cleaved by XhoI and XbaI
restriction enzymes and cloned into the pUCMVMp plasmid
replacing the corresponding nt 2012–4550 wt sequence. The
cDNA constructs were conﬁrmed to harbor the D1/A1 major
splicing pattern in the pUC19MVMpDVP1 clone, and the D2/A2
minor in pUC19MVMpDVP2, by DNA sequencing (Perkin-Elmer
377), and the correct expression of either capsid proteins by
immunoblot (see example in Fig. 5A).
MVMi derivative plasmids previously obtained by site-direc-
ted mutagenesis (Lombardo et al., 2002) to express one capsid
protein were MVMiDVP1 and MVMiDVP2. Plasmids carrying
terminal fragments of the MVM genomes were ampliﬁed in the
Escherichia coli strain JC8111 as previously described (Lombardo
et al., 2002), that preserves the viral hairpins required for
replication. Other plasmids were ampliﬁed in the DH5alpha
E. coli strain.
Insertion of heterologous peptides in the MVM genome
The sc5T4 antibody coding sequence fused with the myc-HA
tag of the plasmid p5T4sc (pBSII/lead/scFVmyc-HA) (Lamikanra
et al., 2005) was cloned into MVMiDVP1 to obtain the VP2i-sc5T4
plasmid. For the sc5T4 n-terminal cloning, the DVP1/VP2-MVMi
sequence extending from the XhoI site upstream from the VP2
coding sequence to the VP2 ATG nt1, was ampliﬁed by PCR
(Perkin/Elmer PCR System 9600) using the oligonucleotides
CCGAATTCATCTCGAGGACCTGGCTTTAG that contains an EcoRI
site, and CAGCTCCATCCCATGGTTTGACTGC that includes the last
11 nt from the VP2 ATG upstream sequence and the 5T4sc four
ﬁrst aas at its 30 end. The sc5T4 sequence corresponding to ATG
nt1 to 285 nt (SacI recognition site) was ampliﬁed using the
complementary oligonucleotide GCAGTCAAACCATGGGATG-
GAGCTG, and the CAGGCTGCGGAGCTCCATGTAGGCTG that con-
tains the SacI site. The resulting fragments puriﬁed from agarose
gels were combined and PCR-ampliﬁed to clone into pUC19 by
EcoRI and SacI digestions to generate p19Nter5T4-VP2. For the
sc5T4 c-terminal cloning, the sc5T4 fragment fused with the
c-myc and HA epitopes was ampliﬁed using the oligonucleotides
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and CTGGTGCCATCACTATGGTGATGGTGATG that includes the
sequence encoding the ﬁrst 2–4 aas of VP2. The MVMiDVP1
sequence was ampliﬁed with the oligonucleotides CATCACCAT-
CACCATAGTGATGGCACCAG encoding the last ﬁve aas of the HA
epitope, and CCGGATCCCCAGTTAACCTCCATCTGTGTTGC contain-
ing HpaI and BamHI sites. The resulting fragments were combined
and PCR-ampliﬁed to clone into pUC19SacI/BamHI-digested plas-
mid to generate p19Cter5T4-VP2. The N- and C-terminal con-
structs were jointed by digestion with SacI and BamHI, and ﬁnally
inserted into MVMiDVP1 plasmid using XhoI and SpeI. The
ATWLPPR peptide (named V1; Binetruy-Tournaire et al., 2000)
was cloned into the pMM984 plasmid by insertion of a fragment
obtained by PCR ampliﬁcation between the XhoI (2071 nt) and
HpaI (3758 nt) sites. The following oligonucleotides were used as
required for PCRs: VPNT-1, CCGAATTCATCTCGAGGACCTGGCTT-
TAG; VPNT-4, CCGGATCCCCAGTTAACCCCCATTTGTGTT; NT-PEP
C1, GCCACGTGGCTGCCGCCGAGGAGTGATGGCACCAGCCAACC; and
NT-PEPC2, CCTCGGCGGCAGCCACGTGGCCATGGTTTGACTGCTTTGCTG.
The V1 insertion was veriﬁed by sequencing in the plasmid DNA
preparation (named pMVMp-V1).
Production and puriﬁcation of viral particles
Puriﬁed wt, chimeric, and pseudotyped virions were prepared
from transfections with the infectious plasmids indicated in the
text. For this purpose, NB324K cells were subjected to large-scale
electroporation according to a previously described methology
(Lombardo et al., 2002), with some modiﬁcations. In brief, multi-
ple batches of 3106 NB324K cells were electroporated (BioRad)
with 10 mg of plasmid(s) DNA and seeded at a density of 1.5106
cells per 90 mm dish in DMEM–10% FCS. The adhered cells were
extensively washed in PBS at 16 h post-transfection (hpt), and
fresh DMEM–5% FCS growth medium replaced. Cell monolayers
were scraped 48 hpt in 50 mM Tris pH 7.5, 2 mM EDTA containing
0.2% SDS, homogenated by gentle sonication and ﬂushing through
a 25-gage needle, and subjected to centrifugation through sucrose
cushion and CsCl equilibrium centrifugation as described (Maroto
et al., 2000). The distribution of viral particles across the gradients
was monitored by hemagglutination with mouse erythrocytes.
The hemagglutination activity of MVM capsids was in the range of
2–6103 HAU/mg of VP protein, as previously described (Rubio
et al., 2005). Those fractions corresponding to the density of MVM
DNA-full particles (1.39–1.41 g/ml) were pooled and extensively
dialyzed against 10 mM Tris pH 7.5, or PBS, and stored at 70 1C
in aliquots until use. Final yield of puriﬁed virions was in the
range of 1–5 ng/3106 transfected cells. 35S-labeled viral parti-
cles were similarly obtained from transfected cells labeling 16–
48 hpt in methionine-free DMEM medium supplemented with
200 mCi/ml of [35S]methionine/cysteine (Amersham SJ5050, UK)
as described (Maroto et al., 2004). Labeled empty capsids and
DNA-ﬁlled virions were puriﬁed by two cycles of CsCl equilibrium
centrifugation and stored as above.
Quantitative analysis of MVM genome encapsidation
NB324K (9–12106) cells electroporated as above with the
indicated MVM genomic plasmids were washed twice with cold
PBS at 48 hpt, scraped and homogenized by ultrasounds in 50 mM
Tris–HCl pH 8, 1 mM EDTA, 0.1 M NaCl, and 0.2% Triton. The
cellular lysates were subjected to centrifugation through a 20%
sucrose cushion, resuspended in HNEM buffer (50 mM Hepes pH
8.0, 150 mM NaCl, 2 mM MgCl2, 1 mM EDTA) supplemented with
0.2% Triton, and layered onto 14 ml of a continuous 5–30%
sucrose gradient in the same buffer as described (Shaw et al.,
2000). Samples were ultracentrifuged at 160,000g in a SW40 rotor(Beckman) at 5 1C for 5 h and fractions were analyzed for MVM
assembled particles by hemagglutination with mouse erythro-
cytes. To determine the viral DNA in the fractions, 0.1 ml of each
sample was diluted to 0.4 N NaOH, and applied onto Nylon ﬁlters
(Amersham) set in a slot-dot apparatus (Hoeffer) under vacuum.
Filters were neutralized with 0.5 M Tris–HCl (pH 7.5), 1.5 M NaCl
during 5 min, baked at 80 1C for 2 h, and used for hybridization
under high stringency with a 5 kbp genomic-length MVM probe
32P-labeled by random priming (Lombardo et al., 2002).
Antibodies
Our collection of antibodies used to identify MVM capsid
proteins (a-VPs), assembled capsids (Capsid-MAb), and mature
DNA-ﬁlled virus exposing the 2Nt domain (a-2Nt) has been
previously described (Maroto et al., 2004; Riolobos et al., 2006).
The VP1 protein subunits were identiﬁed by an antiserum raised
against the 142 aas region speciﬁc to VP1 (a-VP1uR; Cotmore
et al., 1999). A rabbit a-myc antibody (Santa Cruz Biotechnology)
was used to recognize the tag of the 5T4-myc antigen. Antibodies
were used for indirect immunoﬂuorescence (IF), confocal micro-
scopy, and western-blotting, following previously described pro-
cedures (Lombardo et al., 2002; Maroto et al., 2004; Riolobos
et al., 2010).
Determination of virus speciﬁc infectivity
Puriﬁed MVM virions were quantitated by slot-blotting serial
dilution onto nitrocellulose membranes, and determining the
amount of VPs by immunostaining and ECL (Riolobos et al.,
2010). Internal controls were graded amounts of VP2 protein
previously calibrated in respect to BSA by 10% SDS-PAGE staining
with Coomasie blue. To ensure quantitative results, determina-
tions were repeated twice and ﬁlms exposed in the linear
response range. The infectivity was determined by an immuno-
ﬂuorescence assay (IFA) staining with the anti-VPs antibody at
24 hpi (Lombardo et al., 2002). Infectious titers were expressed as
immunoﬂuorescence units (IFU) per ml, which were determined
by duplicate inoculations of NB324K monolayers seeded onto
glass coverslips at a density of 2104 cells/cm2, adding neutra-
lizing anti-MVM capsid antiserum at 6 hpi to avoid reinfections,
and visual counting of most ﬂuorescent foci (VPþ cells) in the
coverslips.
Complementation analysis
NB324K cells were electroporated as above with equivalent
amounts of the plasmid mixtures indicated in the ﬁgures, har-
vested at 48 hpt, and homogenized in PBS by three cycles of
freeze-thawing and untrasounds treatments. The homogenates
were clariﬁed by centrifugation (15 min and 10,000xg at 4 1C) and
the amount of VP proteins in the homogenates estimated by
Western-blotting with the a-VPs antibody. Samples with normal-
ized amounts of VP proteins were innoculated in serial dilutions
onto NB324K monolayers and the number of infectious units
determined by IFA as above.
2Nt cleavage in vitro and in cells
For the analysis of 2Nt sensitivity to proteases in vitro, equal
amounts (0. 01 mg) of gradient-puriﬁed virions were diluted in
50 ml of the following protease buffers: for trypsin (sequencing
grade, Boehringer), 50 mM Tris–HCl, pH 8.0, 5 mM EDTA; for a-
chymotrypsin (Boehringer), 50 mM NH4 HCO3, pH 8; for endo-
proteinase Glu-C (V8, Boehringer), 50 mM sodium phosphate
buffer, pH 7.8. Samples were incubated with the indicated
C. Sa´nchez-Martı´nez et al. / Virology 432 (2012) 45–56 55amounts of each protease for 30 min at 37 1C according to our
previous studies (Maroto et al., 2000), and VP integrity tested by
western-blotting with the a-VPs antibody.
The infectivity of intact and proteases-treated virions (Fig. 4C)
was assessed by ﬁrstly adjusting the sample to DMEM–5% FCS on
ice. The viral samples were inoculated onto NB324K monolayers
at a ratio of 5–15 ng of puriﬁed virion per 105 cells, and adsorp-
tion allowed at 4 1C for 60 min under continuous shaking. After
extensive washing in PBS to remove remaining proteases and
non-adsorpted virions, fresh prewarmed DMEM–5% FCS culture
medium was added, and infectivity quantitated by IFA at 24 hpi.
For the analysis of 2Nt processing in vivo (Fig. 6), NB324K cells
were inoculated with virions samples at the conditions indicated
above, cell extracts prepared at 0 hpi (4 1C) and 4 hpi (37 1C), and
subjected to blotting and immunostaining with the a-VPs anti-
body. For the analysis of 2Nt processing at late times post-
infection (Fig. 3C), NB324K monolayers were inoculated with
35S-labeled puriﬁed viral particles and processed as indicated in
the ﬁgure legend.Acknowledgments
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